Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

CSE:AGN - Post Discussion

Algernon Pharmaceuticals Inc. > AGN.c upcoming milestones
View:
Post by StockDoctor101 on Feb 03, 2023 2:46pm

AGN.c upcoming milestones

Lot of upcoming milestones which could get AGN moving. Look out for data from phase 1 of the DMT study in Q2 of this year along with the beginning of a phase 2b IPF study for chronic cough also set for Q2.

The global stroke treatment market could also reach $15B by 2027, which adds to the significant upside for AGN.
Comment by waves1 on Feb 06, 2023 4:19pm
With one study in progress and another incoming, AGN is has an established plan for this year and could easily see some catalysts here. 
Comment by C10H12N2 on Feb 07, 2023 12:14pm
Without an uplist to NASDAQ this stock will most likely remain in the gutter. People want to see data and uplist ro NASDAQ. They have been royally screwed with the 100 to 1 reverse spilit based on an uplist that never happened. In the meantime, your leaders allowed AlphaNorth (a small investment outfit) to gobble up 13% of the company which disqualifies Algernon from uplisting to NASDAQ for the ...more  
Algernon Pharmaceuticals Inc.